Press Releases 2012
First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System - Oct 10, 2012
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™ Valve System in up to 120 patients with severe...
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial - May 15, 2012
Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™ Aortic Valve System in patients with...
Media Contacts
Rosie Ireland
Corporate Communications
+44 7585403359
rosie.ireland@bsci.com